Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 4/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.47 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853160 | 0.87 | APP (0.49) | ELANEF2APPCTSGHTR1A | |
| SCHEMBL1021663 | 0.84 | CCR5 (0.48) | APPHTR1ADRD2USP28USP25 | |
| SCHEMBL6213896 | 0.84 | CCR5 (0.49) | APPHTR1ADRD2FFAR1CCR5 | |
| SCHEMBL8757373 | 0.83 | ELANE (0.71) | ELANEF2SLC6A2CTSGHTR1A | |
| SCHEMBL6370737 | 0.81 | HTR1A (0.49) | APPHTR1ADRD2USP28USP25 | |
| SCHEMBL11647126 | 0.81 | APP (0.56) | APPHTR1ADRD2FFAR1 | |
| SCHEMBL31375355 | 0.81 | APP (0.56) | APPHTR1ADRD2FFAR1 | |
| SCHEMBL4680227 | 0.81 | USP28 (0.68) | ELANEF2USP28USP25HTT | |
| SCHEMBL2954443 | 0.81 | MAPT (0.60) | ELANEF2PTGER1 | |
| SCHEMBL6212452 | 0.81 | PTGER1 (0.60) | ELANEF2CTSGHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797110-B1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
| CN-101090909-A | Antibacterial amide macrocycles IV | AICURIS GMBH & CO KG (DE) | 2007-12-19 | — | — | CN | disclosed |
| CN-1326870-C | Antibacterial amide macrocycles | BAYER HEALTHCARE AG (DE) | 2007-07-18 | — | — | CN | disclosed |
| EP-1797110-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AiCuris GmbH & Co. KG (DE) | 2007-06-20 | — | — | EP | disclosed |
| US-20070129288-A1 | Antibacterial amide macrocycles | BAYER HEALTHCARE AG (DE) | 2007-06-07 | — | — | US | disclosed |
| US-20070129288-A1 | Antibacterial amide macrocycles | BAYER HEALTHCARE AG (DE) | 2007-06-07 | — | — | US | disclosed |
| CN-1675236-A | Antibacterial amide macrocycles | BAYER HEALTHCARE AG (DE) | 2005-09-28 | — | — | CN | disclosed |
| EP-1526896-A1 | ANTIBACTERIAL ESTER MACROCYCLES | Bayer HealthCare AG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2005033129-A1 | ANTIBACTERIAL AMIDE MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2005-04-14 | — | — | WO | disclosed |
| EP-1515983-A1 | ANTIBACTERIAL AMIDE MACROCYCLES | Bayer HealthCare AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| US-6803457-B1 | ADENOSINE RECEPTORS; FOR REDUCTION OF TISSUE DAMAGE RESULTING FROM HYPOXIA/CARDIOVASCULAR DISORDERS IN MAMMALS/HUMANS | PFIZER, INC. | 2004-10-12 | — | — | US | disclosed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | disclosed |
| WO-2004012816-A1 | ANTIBACTERIAL ESTER MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003106480-A1 | ANTIBACTERIAL AMIDE MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2003-12-24 | — | — | WO | disclosed |
| EP-1216257-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001023399-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129288-A1 | Antibacterial amide macrocycles | AADAC, AAAS, MRPL21 | ELANE 168/4885F2 675/4885SLC6A2 4333/4885 |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | NOD2, AAAS, AADAC | ELANE 922/4885F2 510/4885SLC6A2 4672/4885 |
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | ELANE 1725/4885F2 3841/4885SLC6A2 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.